Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Michael P. Agius, Laura Hevenor, N Connor Payne, Qi Liu, Hyuk-Soo Seo, Romanos Sklavenitis-Pistofidis, Daniel Heilpern-Mallory, Puspalata Bashyal, Michelle P. Aranha, Elizabeth D. Lightbody, Ralph Mazitschek, Sirano Dhe-Paganon, Jun Qi, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 155.

https://doi.org/10.1182/blood-2024-203381

Published: 2024

Journal Articles

Fostering Collaborative Care in Multiple Myeloma: An Update on the Impact of Holistic Education on Decision-Making with Antibody and CAR-T Platforms

Carmine Deluca, Robert Z. Orlowski, Jennifer M. Ahlstrom, Beth M. Faiman, Irene Ghobrial, Michael Beyer, Marina Wanes, Abigail Brugger

Blood (2024) 144 (Supplement 1): 7961.

https://doi.org/10.1182/blood-2024-211443

Published: 2024

Journal Articles

Landscape Assessment of the Perceptions of Distress and Symptom Burden in Patients with Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM)

Elizabeth K. O'Donnell, Jennifer Carroll, Jacqueline Perry, Katherine Padgett, Vidhi Patel, Omar Nadeem, Areej El-Jawahri, Irene Ghobrial, Catherine R. Marinac

Blood (2024) 144 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2024-201747

Published: 2024

Journal Articles

Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Blood (2024) 144 (Supplement 1): 4984.

https://doi.org/10.1182/blood-2024-194368

Published: 2024

Journal Articles

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Rosa Toenges, Jean-Baptiste Alberge, Francesco Corrado, Nayda Bidikian, David M. Cordas Dos Santos, Ankit K. Dutta, Elizabeth D. Lightbody, Romanos Sklavenitis Pistofidis, Adam S. Sperling, Kenneth C. Anderson, Shonali Midha, Yuxin Liu, Jacob P. Laubach, Eric L. Smith, Nikhil C. Munshi, Omar Nadeem, Irene Ghobrial, Gad Getz

Blood (2024) 144 (Supplement 1): 492.

https://doi.org/10.1182/blood-2024-204132

Published: 2024

Journal Articles

Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2024-206540

Published: 2024

Journal Articles

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Nayda Bidikian, Francesco Corrado, Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Rosa Toenges, Jean-Baptiste Alberge, Michelle P. Aranha, Ting Wu, Michael Timonian, Shonali Midha, Elizabeth K. O'Donnell, Yuxin Liu, Sophie Magidson, Ashlee Strutevant, Kenneth C. Anderson, Nikhil C. Munshi, Omar Nadeem, Gad Getz, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 488.

https://doi.org/10.1182/blood-2024-207299

Published: 2024

Journal Articles

Evaluation of Urine cfDNA for Non-Invasive Genomic Characterization in Multiple Myeloma: A Comparative Study with Serum and Bone Marrow Samples

Carl Jannes Neuse, Christoph Schliemann, Cyrus Khandanpour, Georg Lenz, Irene Ghobrial, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7493.

https://doi.org/10.1182/blood-2024-210454

Published: 2024

Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3360.

https://doi.org/10.1182/blood-2024-202653

Published: 2024

Journal Articles

Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Blood (2024) 144 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2024-203937

Published: 2024

Journal Articles

Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 590.

https://doi.org/10.1182/blood-2024-204144

Published: 2024

Journal Articles

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Blood (2024) 144 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2024-209286

Published: 2024

Journal Articles

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1928.

https://doi.org/10.1182/blood-2024-203684

Published: 2024

Journal Articles

Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control

Romanos Sklavenitis-Pistofidis, Ting Wu, Elizabeth D. Lightbody, Yoshinobu Konishi, Mahshid Rahmat, Michael P. Agius, Junko Tsuji, Jean-Baptiste Alberge, Michael Timonian, Ankit K. Dutta, Michelle P. Aranha, Nayda Bidikian, Hadley Barr, Nicholas J. Haradhvala, Moshe Sade-Feldman, Gad Getz, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 1895.

https://doi.org/10.1182/blood-2024-208837

Published: 2024

Journal Articles

Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development

Blood (2024) 144 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2024-205523

Published: 2024

Journal Articles

Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

Blood (2024) 144 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2024-202676

Published: 2024

Journal Articles

A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Blood (2024) 144 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2024-203517

Published: 2024

Journal Articles

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Blood (2024) 144 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2024-205705

Published: 2024

Journal Articles

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Blood (2022) 140 (Supplement 1): 7317–7319.

https://doi.org/10.1182/blood-2022-157302

Published: 2022

Journal Articles

Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

Habib El-Khoury, Luca Bertamini, Jean-Baptiste Alberge, David J. Lee, Ciara Murphy, Grace Fleming, Christian J. Cea-Curry, Maya I. Davis, Jacqueline Perry, Elizabeth D. Lightbody, Dhananjay Sakrikar, Derek Troske, David Barnidge, Mark C. Perkins, Stephen Harding, Gad Getz, Catherine R. Marinac, Irene Ghobrial

Blood (2022) 140 (Supplement 1): 10101–10103.

https://doi.org/10.1182/blood-2022-169380

Published: 2022

NARROW

Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Fostering Collaborative Care in Multiple Myeloma: An Update on the Impact of Holistic Education on Decision-Making with Antibody and CAR-T Platforms

Landscape Assessment of the Perceptions of Distress and Symptom Burden in Patients with Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM)

Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Evaluation of Urine cfDNA for Non-Invasive Genomic Characterization in Multiple Myeloma: A Comparative Study with Serum and Bone Marrow Samples

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control

Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development

Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only